ASCO 2013 - Maintenance Olaparib for Severe Ovarian Cancer and a BRCA mutation - Dr. Jonathan Ledermann

Abstract #5505: Previously, we reported that maintenance treatment with the oral PARP inhibitor olaparib (400 mg bid) led to a significant PFS improvement vs placebo in patients (pts) with platinum-se... Author: oncologyeducation Added: 06/23/2013
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts